This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Genzyme Corporation. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: The Innovations of Bradford Elmer
Introduction
Bradford Elmer is a notable inventor based in Bridgewater, NJ (US). He has made significant contributions to the field of neurodegenerative research, particularly through his innovative work on RNA interference (RNAi) technologies.
Latest Patents
Elmer holds a patent for a groundbreaking invention titled "Variant RNAi against alpha-synuclein." This patent provides RNAi molecules designed to treat neurodegenerative synucleinopathies. The RNAi molecules specifically target the expression of alpha-synuclein (SNCA). Additionally, the patent includes expression constructs, vectors such as rAAV, cells, viral particles, and pharmaceutical compositions that incorporate the RNAi. The methods and kits related to this RNAi are aimed at treating conditions like Parkinson's disease, multiple system atrophy, and dementia with Lewy bodies.
Career Highlights
Bradford Elmer is currently associated with Genzyme Corporation, where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment of various neurodegenerative diseases.
Collaborations
Elmer collaborates with talented individuals in his field, including Maria Carmen Obinu and Brenda Richards. Their combined expertise contributes to the advancement of research in neurodegenerative disorders.
Conclusion
Bradford Elmer's contributions to the field of neurodegenerative research through his innovative patent demonstrate his commitment to improving treatment options for patients. His work at Genzyme Corporation and collaborations with fellow researchers highlight the importance of teamwork in scientific advancements.